Dermatology 2013

Notes: Nassar, Dany

Sbidian, Emilie

Bastuji-Garin, Sylvie

Martin, Ludovic

Dupuy, Alain

eng

Research Support, Non-U.S. Gov’t

Review

2012/08/31 06:00

J Invest Dermatol. 2013 Feb;133(2):371-6. doi: 10.1038/jid.2012.279. Epub 2012 Aug 30.

URL: http://www.ncbi.nlm.nih.gov/pubmed/22931921

Author Address: INSERM U938, Centre de Recherche Saint Antoine, Paris, France.

 

 

Reference Type:  Journal Article

Record Number: 4539Author: Ng, L. C., Lee, Y. Y., Lee, C. K. and Wong, S. M.

Year: 2013

Title: A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia

Journal: Int J Dermatol

Volume: 52

Issue: 1

Pages: 102-5

Date: Jan

Short Title: A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia

Alternate Journal: International journal of dermatology

ISSN: 1365-4632 (Electronic)

0011-9059 (Linking)

DOI: 10.1111/j.1365-4632.2011.05436.x

Accession Number: 23278617

Keywords: Adolescent

Adult

Aged

Dermatologic Agents/*adverse effects

Drug-Induced Liver Injury/*etiology

Female

Humans

Liver/*drug effects

Malaysia

Male

Methotrexate/*adverse effects

Middle Aged

Psoriasis/*drug therapy

Retrospective Studies

Severity of Illness Index

Tertiary Care Centers

Time Factors

Young Adult

Abstract: BACKGROUND: Methotrexate (MTX) is a common and efficacious systemic agent used for the treatment of moderate to severe psoriasis. Nevertheless, its use is associated with the risk of hepatotoxicity. This study was performed to study the association of MTX dose with regards to hepatotoxicity as evidenced by deranged transaminases. METHODS: This was a retrospective review of patients with psoriasis on MTX from 2000 to 2009 at the outpatient dermatology clinic, University Malaya Medical Centre (UMMC). We analyzed patients’ demography, serial laboratory investigations, liver ultrasounds, and liver biopsies of patients on MTX. RESULTS: Sixty-six of 710 (9.30%) patients with psoriasis were prescribed MTX throughout the 10-year period. Among them 57.6% developed deranged transaminases, with six requiring MTX withdrawal due to hepatotoxicity. The mean cumulative dose of MTX at the detection of liver enzyme derangement was 552.3 +/- 596.1 mg. CONCLUSION: A high proportion of patients on MTX had deranged transaminases. However, the number of serious events was low. We concluded from this study that the use of MTX is relatively safe in patients with moderate to severe psoriasis.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295